| 產(chǎn)品編號(hào) | IHC0109H | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 英文名稱 | Human GLP-1 Ready-To-Use IHC Kit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 中文名稱 | 人GLP-1單克隆即用型免疫組化試劑盒 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 別 名 | GCG; GLP 1; glucagon; Glucagon like peptide 1; GRPP; GLP-1(7-36); GLP-1(7-37); Oxyntomodulin; OXM; OXY; GLUC_HUMAN. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 應(yīng)用范圍 | Immunohistochemistry | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 適用樣品基質(zhì) | PFPE tissue | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 描述 | IHC0109 is a ready-to-use IHC kit for staining of GLP-1. The kit provides all reagents, from antigen retrieval to cover slip mounting, that require little to no diluting or handling prior to use. Simply apply the reagents to your sample slide according to the protocol and you're steps away from obtaining high-quality IHC data. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 保存條件 | Please store components at the temperatures indicated on the individual tube labels. The kit is stable for 6 months from the date of receipt. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 產(chǎn)品介紹 |
產(chǎn)品組分及規(guī)格
背景 GCG is also known as GLP1, or Glucagon. Glucagon is a 29-amino acid pancreatic hormone that counteracts the glucose-lowering action of insulin by stimulating glycogenolysis and gluconeogenesis.It is mapped to 2q36-2q37. GLP1, also known as 7-37 for the codons of the preproglucagon molecule which encode it, renders pancreatic beta-cells 'glucose-competent' and may be useful in the treatment of noninsulin-dependent diabetes mellitus. Also, GLP1 is a potent insulin secretagogue.It plays a major role in the enteroinsular axis, accounting, for example, for the finding that plasma insulin levels accompanying oral intake of glucose are greater than those observed when glucose is given intravenously.
石蠟包埋組織的免疫組織化學(xué)方案 1. 脫蠟水化 石蠟切片置于新鮮二甲苯中浸泡脫蠟3次，每次15 min；依次置于不同濃度（100%、95%、90%、80%、70%）乙醇浸泡各5 min，再置于蒸餾水洗滌5 min，重復(fù)3次。 2. 抗原修復(fù) 沸水浴修復(fù)：將100×抗原修復(fù)緩沖液（試劑2）用蒸餾水稀釋成1×抗原修復(fù)緩沖液，放入修復(fù)盒中并提前加熱至95-100℃（注意蓋好以防液體蒸發(fā)），然后將切片放入修復(fù)盒中，在沸水浴環(huán)境中保持外沸狀態(tài)15 min，室溫自然冷卻；用PBS緩沖液（試劑1，將干粉溶解在2L蒸餾水中）清洗5 min，重復(fù)3次。 3. 阻斷內(nèi)源性過氧化物酶 用吸水紙吸去玻片上多余的液體，用免疫組化筆在組織周圍畫圈，加入2-4滴內(nèi)源性過氧化物酶阻斷劑（試劑3），室溫下置于濕盒中孵育15 min，用PBS洗滌5 min，重復(fù)3次。 4. 血清封閉 用吸水紙吸去玻片上多余的液體，加入2-4滴封閉工作液（試劑4），置于濕盒內(nèi)37℃封閉20 min，以減少非特異性染色。 5. 一抗孵育 用吸水紙吸去玻片上多余的液體，加入2-4滴人GLP-1鼠單抗工作液（試劑5），置于濕盒中，4℃孵育過夜或37℃孵育1-2 h。 6. 復(fù)溫 4℃孵育過夜后，室溫下復(fù)溫15 min (若在室溫下孵育一抗，則直接進(jìn)入下一步清洗)；用PBS洗滌5 min，重復(fù)3次。 7. 二抗孵育 用吸水紙吸玻片上多余的液體，加入2-4滴HRP標(biāo)記羊抗鼠IgG工作液（試劑6），置于濕盒中，37℃孵育1-2 h；用PBS洗滌5 min，重復(fù)3次。 8. 顯色 用吸水紙吸去玻片上多余的液體，在每張切片上滴加約50 μL新配制的DAB工作液（試劑7:試劑8:PBS=1:1:18），作用3-5 min。顯微鏡下觀察結(jié)果，達(dá)到合適的顯色強(qiáng)度后，用蒸餾水沖洗切片以終止反應(yīng)，用蒸餾水沖洗5 min，重復(fù)3次。 9. 復(fù)染 滴加適量復(fù)染試劑（試劑9）復(fù)染3-5 min，蒸餾水沖洗5 min，滴加鹽酸酒精分化約30 s，蒸餾水洗滌5 min，重復(fù)2次。 10. 脫水封片 將玻片依次置于不同濃度（70%、80%、90%、95%、100%）乙醇，各5 min；然后置于新鮮二甲苯中浸泡脫蠟3次，每次15 min。用吸水紙吸去多余的二甲苯，滴加適量封片劑（試劑10）在組織上，將蓋玻片蓋在組織上，避免產(chǎn)生氣泡。
注意事項(xiàng) 1. 建議檢測(cè)時(shí)進(jìn)行陰性及陽性對(duì)照，以提高實(shí)驗(yàn)的可靠性。 2. 本品中的配套試劑，請(qǐng)不要用其他生產(chǎn)商產(chǎn)品替換使用。 3. DAB為致癌物質(zhì)，請(qǐng)采取必要的防范措施。 4. PBS洗滌液（試劑1）配制后在4℃可保存一周；抗原修復(fù)液（試劑2）及顯色劑（試劑7和8）的工作液需每次實(shí)驗(yàn)時(shí)現(xiàn)用現(xiàn)配。 *5. 發(fā)表論文時(shí)引用本產(chǎn)品的寫作建議 "IHC0109H, Bioss Antibodies"。引用示例: “Human tissue sections using Human GLP-1 IHC Kit (IHC0109H, Bioss Antibodies) were stained for GLP-1 according to the manufacturer's instructions.” |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 產(chǎn)品圖片 |
Immunohistochemical analysis of paraffin embedded human pancreas tissue slide using IHC0109H (Human GLP-1 IHC Kit).
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
